Incidences of New Prescribing by British Child and Adolescent Psychiatrists: a Prospective Study Over 12 Months

Abstract

Little is known about the epidemiology of pharmacotherapy in the treatment of child psychiatric disorder. This study reports on the systematic prospective collection of instances of new prescribing by child and adolescent mental health services serving a population of approximately four million people in North West England. Diagnostic and demographic information regarding new prescribing by child and adolescent mental health services within Greater Manchester and Lancashire was systematically collected prospectively over two 6-month periods between 2000 and 2002. Within the 12 months studied, there were 845 instances of a drug being newly prescribed to a child or adolescent in the treatment of a psychiatric disorder. In total, 48 different drugs were prescribed for 25 different diagnoses. The eight most commonly prescribed drugs were methylphenidate, methylphenidate/placebo trial, paroxetine, fluoxetine, risperidone, imipramine, dexamphetamine and melatonin, accounting for 73% of all prescribing. There was marked variation between services in the amount of prescribing with significant correlation between prescription of stimulants and prescription of selective serotonin reuptake inhibitor antidepressants. Prescription of medications in the treatment of child psychiatric disorder has become a significant part of child and adolescent mental health practice. However, the evidence base underpinning this usage remains limited, and further high quality therapeutic clinical trials are urgently needed.

Get full access to this article

View all access options for this article.

References

Bramble D (2003) Annotation: the use of psychotropic medications in children: a British view . J Child Psychol Psychiatry 44: 169–179

British Association for Psychopharmacology (1997) Child and learning disability. Psychopharmacology. BAP concensus statement . J Psycho-pharmacol 11: 291–294

British Medical Association & Royal Pharmaceutical Society of Great Britain (2002) British National Formulary Number 44 (September 2002). British Medical Association & Royal Pharmaceutical Society of Great Britain, London

Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Pia Raffaelli M, Rocchi F, Bonati M, ‘t Jong G, de Hoog M, van den Anker J (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries . BMJ 320: 79–82

Emslie G J, Rush J, Weinberg W A, Kowatch R A, Hughes C W, Carmody T, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression . Arch Gen Psychiatry 54: 1031–1037

Gowers S G, Harrington R C, Whitton A, Lelliott P, Beevor A, Wing J, Jezzard R (1999) Brief scale for measuring the outcomes of emotional and behavioural disorders in children. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) . Br J Psychiatry 174: 413–416

Greenhill L L, Halperin J M, Abikoff H (1999) Stimulant medications . J Am Acad Child Adolesc Psychiatry 38: 503–512

Hazell P, O’Connell D, Heathcote D, Robertson J, Henry D (1995) Efficacy of tricyclic antidepressants in treating child and adolescent depression: a meta-analysis . BMJ 310: 897–901

Jensen P S, Bhatara V S, Vitiello B, Hoagwood K, Feil M, Burke L B (1999a) Psychoactive medication prescribing practices for US children: gaps between research and clinical practice . J Am Acad Child Adolesc Psychiatry 38: 557–565

10.

Jensen P S, Kettle L, Roper M T, Sloan M T, Dulcan M K, Hoven C, Bird H R, Bauermeister J J, Payne J D (1999b) Are stimulants over-prescribed? Treatment of ADHD in four US communities . J Am Acad Child Adolesc Psychiatry 38: 797–804

11.

Johnson J, Clark A F (2001) Prescribing of unlicensed medicines or licensed medicines for unlicensed applications in child and adolescent psychiatry . Psychiatr Bull 25: 465–466

12.

Keller M B, Ryan N D, Strober M, Klein R G, Kutcher S P, Birmaher B, Hagino O R, Koplewicz H, Carlson G A, Clarke G N, Emslie G J, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack W H, Sweeney M, Wagner K D, Weller E B, Winters N C, Oakes R, McCafferty J P (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial . J Am Acad Child Adolesc Psychiatry 40: 762–772

13.

Kumra S, Frazier J A, Jacobsen L K, McKenna K, Gordon C T, Lenane M C, Hamburger S D, Smith A K, Albus K E, Alaghband-Rad J, Rapoport J L (1996) Childhood onset schizophrenia: a double blind clozapine haloperidol comparison . Arch Gen Psychiatry 53: 1090–1097

14.

March J S, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E H, Cutler N R, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee F R, Wagner K D, Steiner H (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multi-center randomized controlled trial . JAMA 280: 1752–1756

15.

McNicholas F (2001) Prescribing practices of child psychiatrists in the UK . Child Psychol Psychiatry Rev 6: 166–171

16.

Phillips T, Salmon G, James A C (2003) Prescribing practices in child and adolescent psychiatry: change over time 1993–2000 . Child Adol Ment Health 8: 23–28

17.

Riddle M A, Scahil L, King R A, Hardin M T, Anderson G M, Ort S I, Smith J C, Leckman J F, Cohen D J (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive–compulsive disorder . J Am Acad Child Adolesc Psychiatry 31: 1062–1069

18.

Royal College of Paediatrics and Child Health (2000) The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice. Royal College of Paediatrics and Child Health, London

19.

Shaffer D, Gould M, Brasic J, Ambrosini P, Fischer P, Bird H, Aluwahlia S (1983) A Children’s Global Assessment Scale (CGAS) . Arch Gen Psychiatry 40: 1228–1231

20.

World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva